Peptides for Hepatitis — Evidence-Based Overview

How peptide Targets Peptides for Hepatitis

Hepatitis — inflammation of the liver — encompasses a spectrum of conditions including viral hepatitis (hepatitis A, B, C, D, E), autoimmune hepatitis, alcoholic hepatitis, and non-alcoholic steatohepatitis (NASH). Viral hepatitis B (HBV) and C (HCV) are of particular clinical significance, affecting hundreds of millions of people worldwide and causing chronic liver inflammation that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. While HCV is now curable with direct-acting antiviral therapy, chronic HBV remains a condition requiring long-term management. The immune response to viral hepatitis involves complex interactions between innate and adaptive immunity, with T cell responses being critical for viral clearance and B cell-mediated antibody production providing long-term protection. Peptides that modulate immune function and protect liver tissue are of interest as adjunctive approaches, particularly for chronic HBV where current treatments suppress but rarely cure the infection.

Thymosin alpha-1 (Ta1) has the most established clinical evidence of any peptide for hepatitis treatment. Ta1 is a 28-amino acid thymic peptide that enhances T cell maturation, promotes dendritic cell activation, increases natural killer cell activity, and supports Th1 immune responses — the cell-mediated immune arm that is critical for clearing hepatocytes infected with HBV. Ta1 has been evaluated in multiple clinical trials for chronic hepatitis B, both as monotherapy and in combination with interferon-alpha or nucleoside analogues. Clinical data show that Ta1 can improve HBV e-antigen (HBeAg) seroconversion rates and enhance virological response when combined with standard antiviral therapy. Ta1 is approved for hepatitis B treatment in several countries including China, where it is widely used as an adjunct to standard antiviral therapy. Its safety profile across thousands of treated patients is well-established, with minimal side effects. Importantly, Ta1 modulates rather than broadly stimulates immunity, which is relevant because excessive immune activation in hepatitis can cause hepatic flares and acute-on-chronic liver failure.

BPC-157 has demonstrated hepatoprotective effects in multiple preclinical models relevant to hepatitis. In animal studies, BPC-157 has protected against liver damage induced by alcohol, NSAIDs, and hepatotoxic agents. It has shown the ability to reduce liver enzyme elevations (ALT, AST), decrease hepatic inflammation, and prevent hepatocyte necrosis. BPC-157 also interacts with the nitric oxide system and promotes angiogenesis in liver tissue, which may support hepatic regeneration. In models of liver fibrosis — a consequence of chronic hepatitis — BPC-157 has shown antifibrotic properties. However, BPC-157 has not been studied in viral hepatitis models specifically, and its hepatoprotective evidence is limited to chemical and drug-induced liver injury in animals. Low-dose naltrexone (LDN) has been investigated for chronic hepatitis C, with some early studies suggesting improvements in liver function tests and quality of life. LDN's immune-modulatory effects through transient opioid receptor blockade could theoretically support antiviral immune responses. However, the LDN evidence for hepatitis is limited and inconsistent, and with the advent of highly curative direct-acting antivirals for HCV, the clinical relevance of LDN for hepatitis C has diminished. For hepatitis B, LDN has minimal evidence. The honest assessment is that thymosin alpha-1 is the only peptide with meaningful clinical evidence and regulatory approval for hepatitis (specifically chronic HBV). BPC-157 has preclinical hepatoprotective data but no viral hepatitis evidence. LDN has limited and largely superseded evidence for HCV.